Yale Researchers Make Progress in Advanced Lung Cancer Immunotherapy Recognition and Treatment
A recent Yale study found that a newly developed drug could show promise in slowing the progression of non-small cell lung cancer in patients for whom previous treatments had not been effective. Presented at the World Conference on Lung Cancer in Singapore in September, the study found that an immunotherapy medication called NC318 could increase the effectiveness of existing cancer treatments and provide an alternative treatment for patients who did not respond to prior immunotherapy. “In the end, we saw 28% of our patients who had, what we felt, was benefit from this therapy,” said Scott Gettinger, Chief of Thoracic Oncology at the Yale Cancer Center and the study’s lead author. “Which is promising, considering we don’t have anything else. If what we see early on pans out, then this offers a potential salvage therapy for patients who progressed after chemotherapy and immunotherapy, which is the majority of our patients.”Source: Yale Daily News
AI More Accurately Identifies Patients With Advanced Lung Cancer Who Respond to Immunotherapy
Researchers compared AI-powered digital scoring with traditional manual scoring of the PD-L1 immune biomarker to determine if a new immunotherapy treatment, atezolizumab, could benefit patients with advanced non-small cell lung cancer.
Combination Therapies Benefit Patients With Advanced Non-Small Cell Lung Cancer
An ongoing phase II study led by a Yale Cancer Center researcher reveals that combining pembrolizumab with other treatments reduced the size of target tumors, resulting in a higher response rate for patients with advanced NSCLC.
Enhertu Now NCCN-Preferred Treatment for HER2+ Non-Small Cell Lung Cancer: Patients Should Ask About Genetic Testing
When you or someone you love is diagnosed with stage four lung cancer, the news can be overwhelming. But thanks to new precision medications, the outlook for people with lung cancer that has spread (metastatic) has improved dramatically. The drug Enhertu (generic name trastuzumab deruxtecan) is making headway as the favorable treatment option for patients with refractory late-stage lung cancer. In medicine, refractory or relapsed diseases are conditions that do not respond to treatment. “As Enhertu targets the protein HER2, attached to it is a toxin that hopefully will kill the cancerous cells. It’s targeting a therapy in a precise way by attaching to the tumor to deliver treatment,” Dr. Roy S. Herbst, Chief of Medical Oncology at Yale Cancer Center, told SurvivorNet.Source: SurvivorNet
Adjuvant Immunotherapy in Early-Stage NSCLC — Roy Herbst leads a discussion with Julie Brahmer and Sarah Goldberg
Adjuvant chemotherapy has been the standard of care for patients with resectable non-small cell lung cancer (NSCLC), but newer therapies are entering the mix as well. At the American Society of Clinical Oncology (ASCO) annual meeting, findings from several trials on the role of adjuvant immunotherapy were presented. MedPage Today brought together three expert leaders in the field: Moderator Roy Herbst, MD, PhD, of Yale Cancer Center in New Haven, Connecticut, is joined by Julie Brahmer, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, and Sarah Goldberg, MD, MPH, also of Yale Cancer Center, for a virtual roundtable discussion. This second of four exclusive episodes focuses on NSCLC treatment in the adjuvant setting.Source: MedPage Today
Narjust Florez, MD, and Roy S. Herbst, MD, NSCLC: Overall Survival Analysis From the ADAURA Trial of Osimertinib
Narjust Florez, MD, of Dana-Farber Cancer Institute, and Roy S. Herbst, MD, PhD, of Yale Cancer Center, discuss new phase III findings on osimertinib, a third-generation, central nervous system EGFR-TKI, which demonstrated an unprecedented overall survival benefit for patients with EGFR-mutated, stage IB–IIIA non–small cell lung cancer after complete tumor resection, with or without adjuvant chemotherapy (Abstract LBA3).Source: The ASCO Post
A New Pill Could Cut the Risk of Lung Cancer Death in Half—Here’s Everything You Need To Know About This Revolutionary Treatment
Lung cancer is one of the most common cancers in the United States and the leading cause of cancer deaths—it was responsible for almost a quarter of cancer deaths in 2020. But now, clinical trial results show that a pill could be a game-changer (and lifesaver) for lung cancer patients.Source: Parade
Lung Cancer Pill Explained: How This Breakthrough Development May Lower Risk Of Fatality? Experts Speak
Lung cancer has long been a formidable adversary, with its high mortality rates and limited treatment options. However, this new development brings a ray of hope to patients and healthcare professionals alike.Source: India.com
A ‘penicillin moment’ in war against cancer?
While a cure for cancer still seems like a long way off, there are remarkable advancements in tackling the disease in the lungs, pancreas and cervix. We hear about some of those breakthroughs, including a study that suggests a daily pill can significantly cut lung cancer mortality.Source: The Current with Matt Galloway
Gene-Targeted Drug Tagrisso Cuts Death Rate in Half for Patients With Early-Stage Lung Cancer
Once-a-day use of the targeted cancer pill Tagrisso (osimertinib) cut the five-year death rate in half for a subset of patients with early-stage lung cancer, a new clinical trial shows.Source: U.S. News and World Report HealthDay
Osimertinib significantly improves survival following surgery for patients with non-small cell lung cancer who are EGFR+ in the earliest stages
New research presented by Dr. Roy Herbst at the American Society for Clinical Oncology annual meeting in Chicago shows that Osimertinib (Tagrisso) significantly improves survival following surgery for patients with non-small cell lung cancer who are EGFR+ in the earliest stages.Source: Al Jazeera Media View